Overview
ALNY market data
Price History
ALNY price chart · 1M
- O
- 234.32
- H
- 237.69
- L
- 231.36
- C
- 231.88
- Vol
- 82,977.00
Daily history from Jan 4, 2016
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $234.32
- Previous Close
- $233.99
- Day High
- $237.69
- Day Low
- $231.36
- 52 Week High
- $494.83
- 52 Week Low
- $197.95
- 7 Day Return
- -0.34%
- 30 Day Return
- -3.16%
- 90 Day Return
- -14.95%
- 1 Year Return
- -51.82%
- Daily Notional Volume
- $19.2M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 37.17 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.33 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.37 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 16.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $197.81 – $495.55 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $30B · P/B 66.57 · P/S 6.25.
Company News
10 captured
Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $253Benzinga ·
argenx Meets Primary Endpoint in Phase II Celiac Disease StudyZacks Investment Research ·
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzGlobenewswire Inc ·